Platelet function tests in clinical cardiology: Unfulfilled expectations

Journal of the American College of Cardiology

Volumn 61, Issue 21, 2013, Pages 2115-2129

  Gorog, Diana A ^a   Fuster, Valentin ^b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

aggregation; PCI; platelets; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOTTING PARAMETERS; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC VALUE; DRUG ELUTING STENT; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTOPENIA; THROMBOSIS;

BLOOD PLATELETS; CARDIOLOGY; HUMANS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; THROMBOSIS;

EID: 84877949145     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.11.080     Document Type: Review

References (121)

1. S.K. Kundu, E.J. Heilmann, R. Sio, C. Garcia, R.M. Davidson, R.A. Ostgaard Description of an in vitro platelet function analyzer - PFA-100 Semin Thromb Hemost 21 Suppl 2 1995 106 112
2. J.W. Smith, S.R. Steinhubl, A.M. Lincoff Rapid platelet-function assay: an automated and quantitative cartridge-based method Circulation 99 1999 620 625
3. A. Matzdorff Platelet function tests and flow cytometry to monitor antiplatelet therapy Semin Thromb Hemost 31 2005 393 399
4. M.D. Trip, V.M. Cats, F.J. van Capelle, J. Vreeken Platelet hyperreactivity and prognosis in survivors of myocardial infarction N Engl J Med 322 1990 1549 1554
5. H.K. Breddin, R. Lippold, M. Bittner, C.M. Kirchmaier, H.J. Krzywanek, J. Michaelis Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG study. Haemostatic parameters as risk factors in healthy volunteers Atherosclerosis 144 1999 211 219
6. K. Eto, S. Takeshita, M. Ochiai, Y. Ozaki, T. Sato, T. Isshiki Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability Cardiovasc Res 40 1998 223 229
7. D.L. Yee, A.L. Bergeron, C.W. Sun, J.F. Dong, P.F. Bray Platelet hyperreactivity generalizes to multiple forms of stimulation J Thromb Haemost 4 2006 2043 2050
8. D.L. Yee, C.W. Sun, A.L. Bergeron, J.F. Dong, P.F. Bray Aggregometry detects platelet hyperreactivity in healthy individuals Blood 106 2005 2723 2729
9. P.A. Gurbel, K.P. Bliden, J. DiChiara Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study Circulation 115 2007 3156 3164
10. C. Perneby, N.H. Wallen, C. Rooney, D. Fitzgerald, P. Hjemdahl Dose- and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 2006 652 658
11. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
12. G. Kidson-Gerber, J. Weaver, R. Gemmell, A.M. Prasan, B.H. Chong Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease Heart Lung Circ 19 2010 234 242
13. E.L. Grove, A.M. Hvas, H.L. Johnsen A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease Thromb Haemost 103 2010 1245 1253
14. A.L. Frelinger, Y. Li, M.D. Linden Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests J Thromb Haemost 6 2008 2035 2044
15. P. Harrison The influence of citrate concentrations on PFA-100 closure times, platelet hyper-reactivity and aspirin monitoring Thromb Res 126 2010 e137 e138
16. J.L. Mehta, B. Mohandas Aspirin resistance: fact or fiction? A point of view World J Cardiol 2 2010 280 288
17. D.A. Gorog, J.M. Sweeny, V. Fuster Antiplatelet drug 'resistance' Part 2: laboratory resistance to antiplatelet drugs - fact or artifact? Nat Rev Cardiol 6 2009 365 373
18. A.M. Gori, R. Marcucci, A. Migliorini Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 2008 734 739
19. S. Saraf, C. Christopoulos, I.B. Salha, D.J. Stott, D.A. Gorog Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction J Am Coll Cardiol 55 2010 2107 2115
20. M. Lordkipanidze, J.G. Diodati, E. Schampaert, D.A. Palisaitis, C. Pharand Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease Am J Cardiol 104 2009 1189 1193
21. T. Cuisset, C. Frere, R. Poyet Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting Arch Cardiovasc Dis 103 2010 39 45
22. C. Varenhorst, S. James, D. Erlinge Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin Am Heart J 157 2009 562 e1-9
23. H.J. Bouman, E. Parlak, J.W. van Werkum Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel J Thromb Haemost 8 2010 482 488
24. C. Bal Dit Sollier, N. Berge, B. Boval, M. Dubar, L. Drouet Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel Thromb Haemost 104 2010 571 581
25. J.W. van Werkum, H.J. Bouman, N.J. Breet, J.M. ten Berg, C.M. Hackeng The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flowcytometric VASP assay and optical aggregometry Thromb Res 126 2010 44 49
26. M. Lordkipanidze, C. Pharand, T.A. Nguyen, E. Schampaert, D.A. Palisaitis, J.G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur Heart J 29 2008 2877 2885
27. L. Bonello, U.S. Tantry, R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
28. M.A. Gaglia, R. Torguson, R. Pakala Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention J Interv Cardiol 24 2011 529 534
29. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
30. Z.M. Chen, L.X. Jiang, Y.P. Chen Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
31. B. Aleil, L. Jacquemin, F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study J Am Coll Cardiol Intv 1 2008 631 638
32. M.J. Price, P.B. Berger, P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
33. S.R. Mehta, J.P. Bassand, S. Chrolavicius Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
34. L. Bonello, L. Camoin-Jau, S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
35. L. Bonello, L. Camoin-Jau, S. Armero Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
36. M. Valgimigli, G. Campo, N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
37. S. Lischke, D.J. Schneider Recent developments in the use of antiplatelet agents to prevent cardiovascular events Future Cardiol 7 2011 403 413
38. 12-mediated platelet function Thromb Haemost 103 2010 1210 1217
39. S.S. Brar, J. ten Berg, R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
40. G. Campo, M. Valgimigli, D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study J Am Coll Cardiol 48 2006 2178 2185
41. G. Parodi, R. Marcucci, R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
42. A.D. Atiemo, L.S. Ng'Alla, D. Vaidya, M.S. Williams Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain J Thromb Thrombolysis 25 2008 173 178
43. N.J. Breet, J.W. van Werkum, H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
44. A. Modica, F. Karlsson, T. Mooe The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction Thromb J 7 2009 12
45. J. Gianetti, M.S. Parri, S. Sbrana Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study Thromb Res 118 2006 487 493
46. G.F. Hobikoglu, T. Norgaz, H. Aksu The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy Can J Cardiol 23 2007 201 206
47. T. Mueller, B. Dieplinger, W. Poelz, M. Haltmayer Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease Clin Appl Thromb Hemost 15 2009 652 659
48. L. Bonello, F. Paganelli, M. Arpin-Bornet Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
49. 12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention: a case-control study Am Heart J 162 2011 363 371
50. C. Frere, T. Cuisset, J. Quilici ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome Thromb Haemost 98 2007 838 843
51. L. Bonello, M. Pansieri, J. Mancini High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
52. L. Bonello, J. Mancini, M. Pansieri Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel J Thromb Haemost 10 2012 1999 2005
53. T.L. Pinto Slottow, L. Bonello, R. Gavini Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis Am J Cardiol 104 2009 525 530
54. Y.G. Ko, J.W. Suh, B.H. Kim Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention Am Heart J 161 2011 383 390
55. R. Marcucci, A.M. Gori, R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
56. D.W. Park, S.W. Lee, S.C. Yun A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation J Am Coll Cardiol 58 2011 2630 2639
57. J.L. Reny, P. Berdague, A. Poncet Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study Circulation 125 2012 3201 3210
58. S.G. Ahn, S.H. Lee, J.H. Yoon Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction J Am Coll Cardiol Intv 5 2012 259 267
59. L.H. Yu, M.H. Kim, H.Z. Zhang Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome Korean Circ J 42 2012 382 389
60. P. Paulu, P. Osmancik, P. Tousek Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease J Thromb Thrombolysis 2012 Oct 6 [E-pub ahead of print]
61. M.J. Price, D.J. Angiolillo, P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
62. Stone G. ADAPT-DES: a large-scale, prospective, multicenter registry examining the relationship of platelet responsiveness and stent thrombosis after DES implantation. Paper presented at: TCT 2011: Transcatheter Cardiovascular Therapeutics 23rd Annual Scientific Symposium; October 27, 2011; San Francisco, CA.
63. G. Greenberg, A. Assali, H. Vaknin-Assa Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction Am J Cardiol 105 2010 435 440
64. S.C. Goncalves, M. Labinaz, M. Le May Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention Am J Cardiol 107 2011 204 209
65. S.J. Turner, T.R. Ketch, S.K. Gandhi, D.C. Sane Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes Am Heart J 155 2008 806 816
66. S.P. Lee, K.W. Park, D.H. Shin Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy J Atheroscler Thromb 18 2011 914 923
67. R. Marcucci, A.M. Gori, R. Paniccia High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting Thromb Haemost 104 2010 279 286
68. F. Mangiacapra, G. Patti, E. Barbato A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study J Am Coll Cardiol Intv 5 2012 281 289
69. A.J. Kirtane, H. Parise, B. Witzenbichler Does platelet function testing add significant incremental risk stratification to unselected patients undergoing DES implantation? The ADAPT-DES study [Abstract] J Am Coll Cardiol 59 Suppl 1 2012 E292
70. J.L. Mega, S.L. Close, S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
71. T. Cuisset, J. Quilici, W. Cohen Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome Am J Cardiol 108 2011 760 765
72. J.L. Mega, W. Hochholzer, A.L. Frelinger 3rd Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
73. L. Bonello, S. Armero, O. Ait Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
74. D. Alexopoulos, G. Dimitropoulos, P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping J Am Coll Cardiol Intv 4 2011 403 410
75. M.J. Price, A.R. Carson, S.S. Murray First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the Genotype Information and Functional Testing (Gift) exome study J Am Coll Cardiol 59 Suppl 2012 E9
76. H.J. Bouman, E. Schomig, J.W. van Werkum Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
77. J.S. Hulot, J.P. Collet, G. Cayla CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients Circ Cardiovasc Interv 4 2011 422 428
78. J.P. Lewis, A.S. Fisch, K. Ryan Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response Clin Pharmacol Ther 90 2011 568 574
79. D. Sibbing, W. Koch, S. Massberg No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
80. J.D. Snoep Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy Circ Cardiovasc Interv 4 2011 401 404
81. J.L. Mega, T. Simon, J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
82. J.S. Hulot, J.P. Collet, J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
83. M.V. Holmes, P. Perel, T. Shah, A.D. Hingorani, J.P. Casas CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
84. T. Bauer, H.J. Bouman, J.W. van Werkum, N.F. Ford, J.M. ten Berg, D. Taubert Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
85. T.T. Tsai, P.M. Ho, S. Xu Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent) Circ Cardiovasc Interv 3 2010 230 235
86. C. Geeganage, R. Wilcox, P.M. Bath Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis BMC Med 8 2010 36
87. K. Tsukahara, K. Kimura, S. Morita Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents Circ J 74 2010 679 685
88. D. Sibbing, S. Schulz, S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
89. G. Patti, V. Pasceri, V. Vizzi, E. Ricottini, G. Di Sciascio Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) Am J Cardiol 107 2011 995 1000
90. G. Campo, G. Parrinello, P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
91. T. Cuisset, G. Cayla, C. Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
92. T. Cuisset, J. Quilici, M. Loosveld Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes Am Heart J 164 2012 327 333
93. D. Alexopoulos, A. Galati, I. Xanthopoulou Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
94. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schomig, A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
95. R. Altman, A.J. Rivas, C.D. Gonzalez Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study Thromb J 10 2012 3
96. D.M. Monroe, M. Hoffman, H.R. Roberts Platelets and thrombin generation Arterioscler Thromb Vasc Biol 22 2002 1381 1389
97. J.L. Ferreiro, D. Sibbing, D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
98. S.M. Nazarian, J.B. Thompson, T.J. Gluckman Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy Thromb Res 126 2010 379 383
99. M.J. Maxwell, E. Westein, W.S. Nesbitt, S. Giuliano, S.M. Dopheide, S.P. Jackson Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation Blood 109 2007 566 576
100. D.L. Bark Jr., D.N. Ku Wall shear over high degree stenoses pertinent to atherothrombosis J Biomech 43 2010 2970 2977
101. W.S. Nesbitt, E. Westein, F.J. Tovar-Lopez A shear gradient-dependent platelet aggregation mechanism drives thrombus formation Nat Med 15 2009 665 673
102. Z.M. Ruggeri, J.N. Orje, R. Habermann, A.B. Federici, A.J. Reininger Activation-independent platelet adhesion and aggregation under elevated shear stress Blood 108 2006 1903 1910
103. A.J. Reininger, H.F. Heijnen, H. Schumann, H.M. Specht, W. Schramm, Z.M. Ruggeri Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress Blood 107 2006 3537 3545
104. A. Undas, K.E. Brummel-Ziedins, K.G. Mann Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood 109 2007 2285 2292
105. 12 receptors enhance signalling towards procoagulant activity and thrombin generation A study with healthy subjects and patients at thrombotic risk Thromb Haemost 93 2005 1128 1136
106. M.L. Kalb, L. Potura, G. Scharbert, S.A. Kozek-Langenecker The effect of ex vivo anticoagulants on whole blood platelet aggregation Platelets 20 2009 7 11
107. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
108. N.R. Cook Use and misuse of the receiver operating characteristic curve in risk prediction Circulation 115 2007 928 935
109. M.A. Hlatky, P. Greenland, D.K. Arnett Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
110. E.J. Favaloro Internal quality control and external quality assurance of platelet function tests Semin Thromb Hemost 35 2009 139 149
111. M. Cattaneo, C.P. Hayward, K.A. Moffat, M.T. Pugliano, Y. Liu, A.D. Michelson Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH J Thromb Haemost 7 2009 1029
112. E.J. Favaloro, R. Bonar External quality assurance for the PFA-100(R) J Thromb Haemost 9 2011 878 880
113. P.A. Gurbel, K.P. Bliden, K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
114. J.T. Brandt, C.D. Payne, S.D. Wiviott A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66 e9-16
115. D. Trenk, G.W. Stone, M. Gawaz A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
116. T. Jernberg, C.D. Payne, K.J. Winters Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
117. J.L. Mega, E. Braunwald, S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
118. M.L. O'Donoghue, D.L. Bhatt, S.D. Wiviott Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes trial Circulation 123 2011 1843 1853
119. R.C. Becker, D.J. Moliterno, L.K. Jennings Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
120. P.A. Gurbel, K.P. Bliden, K. Guyer, N. Aggarwal, U.S. Tantry Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 119 2007 563 570
121. P.A. Gurbel, K.P. Bliden, K. Guyer Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study J Am Coll Cardiol 46 2005 1820 1826